Cangrelor
Back to searchMolecule Structure
Scientific Name
Cangrelor
Description of the Drug
Cangrelor is a P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06441
http://www.drugbank.ca/drugs/DB06441
Brand Name(s)
Not Available
Company Owner(s)
Chiesi Usa Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Purinergic receptor P2Y12 | SINGLE PROTEIN | ANTAGONIST | CHEMBL2001 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL6113860 | ||
PharmGKB | PA165945763 | ||
Human Metabolome Database | HMDB0240386 | ||
DrugBank | DB06441 | ||
PubChem: Thomson Pharma | 14889113 | 14840449 | |
PubChem | 9854012 | ||
Nikkaji | J1.089.474C | ||
BindingDB | 50118225 | ||
EPA CompTox Dashboard | DTXSID90167651 | ||
DrugCentral | 5006 | ||
ChemicalBook | CB62451277 | ||
Guide to Pharmacology | 1776 | ||
rxnorm | KENGREAL | CANGRELOR | CANGRELOR TETRASODIUM |
ChEBI | 90841 | ||
ZINC | ZINC000085537017 |